1. Medtech Insight

St. Jude First To Market Leadless Pacemaker With Nanostim Buy

St. Jude paid $123.5 million and agreed to up to $65 million in additional milestone payments to acquire Nanostim and its first-in-class leadless pacemaker, which has just earned a CE mark and is expected to launch in select European markets soon.

St. Jude Medical Inc. completed its acquisition of Nanostim Inc. on Oct. 14 and announced a European CE mark for the firm’s Nanostim leadless pacemaker the same day. St. Jude says it will launch the device shortly in select European countries, making it the first commercially available leadless pacemaker.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Opportunity For Medtech To Contribute To EU Cybersecurity Recommendations

 
• By Amanda Maxwell

The deadline for comments is 30 June 2025

Dexcom Wins FDA Nod For 15-Day G7 CGM, Closing Gap With Abbott’s 14-Day FreeStyle Libre

 
• By Marion Webb

Dexcom announced it received US clearance for its 15-day CGM, which has a MARD of 8.0% and is expected to launch in the second half of 2025 to allow for integration with insulin pumps.

Diagnostics Are Essential, But How Can Companies Ensure A Fair Price?

 
• By Barnaby Pickering

Biotech and pharma are increasingly clear about one thing: They need diagnostics. But with prices suppressed, how have diagnostics companies proven their utility without going under?